

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Health Technology Appraisal

Etanercept, infliximab, adalimumab & golimumab for the treatment of psoriatic arthritis (including a review of existing guidance nos. 104 & 125)

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Abbott Laboratories (adalimumab) • Schering-Plough (infliximab, golimumab) • Wyeth Pharmaceuticals (etanercept) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action on Pain • Afiya Trust • Age Concern England • Arthritic Association • Arthritis & Musculoskeletal Alliance (ARMA) • Arthritis Care • BackCare • Black Health Agency • British Ethnic Health Awareness Foundation (BEHAF) • Changing Faces • Chinese National Healthy Living Centre • Confederation of Indian Organisations • Counsel and Care • Equalities National Council • Help the Aged • Leonard Cheshire Disability • Let's Face It • Muslim Council of Great Britain • Muslim Health Network • Pain Concern 	<p><u>General</u></p> <ul style="list-style-type: none"> • Age Concern Cymru • Board of Community Health Councils in Wales • British National Formulary • Department of Health, Social Services and Public Safety for Northern Ireland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Public Health Service for Wales • NHS Alliance • NHS Confederation • NHS Purchasing and Supply Agency • NHS Quality Improvement Scotland • Scottish Medicines Consortium <p><u>Comparator manufacturers</u></p> <ul style="list-style-type: none"> • Actavis UK (sulfasalazine) • Almus Pharmaceuticals (sulfasalazine) • AlphaPharma (sulfasalazine) • Generics (UK) (sulfasalazine) • GlaxoSmithKline (azathioprine) • Goldshield Pharmaceuticals (methotrexate) • Hospira UK (methotrexate) • IVAX Pharmaceuticals UK (sulfasalazine) • Kent Pharmaceuticals (sulfasalazine)

National Institute for Health and Clinical Excellence

Etanercept, infliximab, adalimumab & golimumab for the treatment of psoriatic arthritis (including a review of existing guidance nos. 104 & 125)

Issue date: March 2009

APPENDIX A

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Pain Relief Foundation • Psoriasis Association • Psoriasis and Psoriatic Arthritis Alliance • RADAR - Royal Association for Disability & Rehabilitation • Skin Care Campaign • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • British Association for Services to the Elderly • British Association of Dermatologists • British Dermatological Nursing Group • British Geriatrics Society • British Health Professionals in Rheumatology • British Institute of Musculoskeletal Medicine • British Orthopaedic Association • British Skin Foundation • British Society for Rheumatology • British Society of Rehabilitation Medicine • Community Practitioners and Health Visitors Association • Pain Society • Primary Care Dermatology Society • Primary Care Rheumatology Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine – Intellectual Disabilities Forum • United Kingdom Clinical Pharmacy Association 	<ul style="list-style-type: none"> • Novartis Pharmaceuticals (ciclosporin) • Pfizer (methotrexate, sulfasalazine) • Sanofi-Aventis (leflunomide) • Waymade Healthcare (sulfasalazine) • Wockhardt UK (methotrexate) • Wyeth Pharmaceuticals (methotrexate) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Arthritic Research Campaign • British Epidermo-Epidemiology Society • Cochrane Skin Group - Centre of Evidence-based Dermatology, University of Nottingham • Chronic Pain Policy Coalition • MRC Clinical Trials Unit • National Institute for Health Research • Policy Research Institute on Ageing and Ethnicity • Research Institute for the Care of the Elderly • Skin Research Centre • Skin Treatment and Research Trust (START) • Society for Back Pain Research • United Kingdom Clinical Research Network <p><u>Assessment team</u></p> <ul style="list-style-type: none"> • Centre for Reviews and Dissemination, University of York and Centre for Health Economics • National Institute for Health Research Health Technology Assessment Programme <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Collaborating Centre for Primary Care

National Institute for Health and Clinical Excellence

Etanercept, infliximab, adalimumab & golimumab for the treatment of psoriatic arthritis (including a review of existing guidance nos. 104 & 125)

Issue date: March 2009

APPENDIX A

Consultees	Commentators (no right to submit or appeal)
<u>Others</u> <ul style="list-style-type: none">• Department of Health• Hull Teaching PCT• Luton Teaching PCT• Welsh Assembly Government	<u>Associated Public Health Groups</u> <ul style="list-style-type: none">• None

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

National Institute for Health and Clinical Excellence

Etanercept, infliximab, adalimumab & golimumab for the treatment of psoriatic arthritis (including a review of existing guidance nos. 104 & 125)

Issue date: March 2009

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and all non-manufacturers/sponsors consultee organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Assessment team

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).

National Institute for Health and Clinical Excellence

Etanercept, infliximab, adalimumab & golimumab for the treatment of psoriatic arthritis (including a review of existing guidance nos. 104 & 125)

Issue date: March 2009